U.S. FDA Approves New MENTOR ® MemoryGel BOOST™ Breast Implant
Irvine, Calif., (January 13, 2021) – Mentor Worldwide LLC, the number one global brand in breast aesthetics, and part of the Johnson & Johnson Medical Devices Companies** today announced that the U.S. Food and Drug Administration (FDA) approved the MENTOR® MemoryGel BOOST™ Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for surgeons in the United States in early 2022. Nearly 400,000 women undergo breast implant surgeries every year in the U.S.[1], and selecting an implant is a v...
Source: Johnson and Johnson - January 13, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Biocon Biologics says clinical study for drug Itolizumab initiated in India after approval from DCGI
Biocon's partner US-based Equillium Inc has expanded its 'EQUALISE' study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 23, 2021 Category: Pharmaceuticals Source Type: news

SARS-CoV2 in a Lupus Patient Treated With Hydroxychloroquine SARS-CoV2 in a Lupus Patient Treated With Hydroxychloroquine
Was this COVID-19 patient's decreased immune response a result of his being treated with hydroxychloroquine for lupus?Journal of Medical Case Reports (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 21, 2021 Category: Intensive Care Tags: Family Medicine/Primary Care Journal Article Source Type: news

An Engineer ’s Perspective on Autoimmunity
Erika Moore builds biomaterials to study disparate lupus outcomes. (Source: The Scientist)
Source: The Scientist - December 10, 2021 Category: Science Tags: Sponsored Article Source Type: news

How Long Can You Live With Lupus Nephritis?
Title: How Long Can You Live With Lupus Nephritis?Category: Diseases and ConditionsCreated: 12/9/2021 12:00:00 AMLast Editorial Review: 12/9/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - December 9, 2021 Category: Nutrition Source Type: news

SLE Treatment Updates From ACR 2021 SLE Treatment Updates From ACR 2021
Systemic lupus erythematosus updates from ACR 2021 are discussed by Dr Joan Merrill, who reviews data on a novel agent, a post-hoc analysis of BLISS-LN, and late-breaking BLISS-BELIEVE results.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

Adding Rituximab to Belimumab Offers No Help for Lupus Adding Rituximab to Belimumab Offers No Help for Lupus
The combination of rituximab and belimumab was associated with a longer duration of response, but there was no benefit of belimumab alone for disease control at 1 year.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 15, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Lupus in Remission Flares More Often When Reducing, Stopping HCQ Lupus in Remission Flares More Often When Reducing, Stopping HCQ
It's clear that more flares occur when patients in remission or low disease activity stop or reduce hydroxychloroquine, but it's important to consider this effect in different age groups, too.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - November 9, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Distinct Molecular Signatures for Subsets of Patients With CLE Distinct Molecular Signatures for Subsets of Patients With CLE
The findings of this study support a diverse molecular profile in cutaneous lupus erythematosus, opening the door for targeted therapies for different subsets of patients with the disease.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Aspirin Lowered Preeclampsia Risk in Real-World Lupus Study Aspirin Lowered Preeclampsia Risk in Real-World Lupus Study
A prospective, single-center study of pregnancies during 1995 –2020 showed a reduced risk for preeclampsia among high-risk women with systemic lupus erythematous who received low-dose aspirin.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 19, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

' Multimorbidity' More Commonly Seen in People With Lupus'Multimorbidity' More Commonly Seen in People With Lupus
Two studies find that patients with either systemic or cutaneous disease have higher rates of multiple comorbidities, including those commonly reported before and those less frequently associated.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Lupus sufferers pleaded for hydroxychloroquine before Clive Palmer ’s doses were destroyed
Drug ’s potential as Covid treatment, since dispelled, affected availability for people with proven medical needGet our free news app;get our morning email briefingLupus sufferers pleaded for more supplies of hydroxychloroquine two months before the federal government told billionaire Clive Palmer it didn ’t want more of the 33m doses he wanted to donate as a potential Covid-19 treatment.One tonne of Palmer ’s hydroxychloroquine – equivalent to 5m doses – was destroyed after it was left unclaimed in Melbourne due to a lengthy standoff with the commonwealth, Guardian Australiarevealed on Wednes...
Source: Guardian Unlimited Science - October 14, 2021 Category: Science Authors: Christopher Knaus Tags: Clive Palmer Australia news Health Coronavirus Medical research Source Type: news

What Are the Symptoms of Lupus in a Woman
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 14, 2021 Category: General Medicine Source Type: news

Lupus May Confer Higher Risk of Death From COVID-19 Lupus May Confer Higher Risk of Death From COVID-19
SLE had a greater impact on mortality and other poor outcomes than all the other comorbidities considered in a cross-sectional study of patients with COVID-19 in Brazil.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - October 14, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Lupus & cora 2021 lupus & cora 2021
Read clinically focused news coverage of key developments from LUPUS& CORA 2021.Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2021 Category: Consumer Health News Tags: None Conference Coverage Source Type: news

LUPUS and CORA 2021 LUPUS and CORA 2021
Read clinically focused news coverage of key developments from LUPUS& CORA 2021.Medscape Rheumatology (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - October 11, 2021 Category: Rheumatology Tags: Rheumatology Conference Coverage Source Type: news

Arthritis: Best anti-inflammatory beverage to provide effective pain relief for joints
INFLAMMATORY arthritis is characterised by painful, swollen and tender joints. Common forms include: rheumatoid arthritis , psoriatic arthritis , systemic lupus erythematosus , gout and ankylosing spondylitis . (Source: Daily Express - Health)
Source: Daily Express - Health - October 8, 2021 Category: Consumer Health News Source Type: news

How to Maintain Your Social Life When You Have IBD
About two years ago, as Samantha Plevney was dealing with a major Crohn’s disease flare-up, she decided to tell her gastroenterologist how it was affecting her emotional health. “I told him that I’m alive but I’m not living,” she recalls. “Not being able to see my friends because of the uncertainty of my health situation was making me feel worse. I think people with IBD, and their doctors, tend to focus on physical symptoms, and for good reason. But the mental-health effect that comes from social support is huge.” Inflammatory bowel disease (IBD) encompasses two conditions—Cr...
Source: TIME: Health - October 5, 2021 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Source Type: news

What Looks Like Acrocyanosis?
Discussion Acrocyanosis is a peripheral vascular disease where the skin and mucous membranes have a persistent, painless, deep-bluish color due to decreased oxygenated blood which usually is benign. The deoxygenated blood can be due to a central cause such as cyanotic congenital heart disease or localized problems often due to vasospasm. Hands and feet are the most common areas affected. It is thought that there is “…vasospasm of the cutaneous arteries, and arterioles along with compensatory dilatation in the capillary and post capillary venules caus[ing] cyanosis and sweating.” Palms and soles may or ma...
Source: PediatricEducation.org - September 27, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Consumer Health: What do you know about rheumatic diseases?
September is Rheumatic Disease Awareness Month, which makes this a good time to learn about four common rheumatic diseases: ankylosing spondylitis, gout, juvenile idiopathic arthritis and lupus. Ankylosing spondylitis Ankylosing spondylitis is an inflammatory disease that can cause some of the small bones in your spine to fuse. This fusing makes the spine less flexible and can result in a hunched-forward posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing spondylitis… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 20, 2021 Category: Databases & Libraries Source Type: news

Thalidomide and Lenalidomide for Refractory SLE/CLE Thalidomide and Lenalidomide for Refractory SLE/CLE
What do we currently know about the safety and efficacy of these drug options for the treatment of refractory systemic/cutaneous lupus erythematosus?Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

What Are the Advantages and Disadvantages of Different Renal Replacement Therapies?
Discussion Kidneys are amazing in that they filter the blood, eliminate toxins, balance fluids and electrolytes plus have a lot of reserve to do the job they need to do even when injured. Therefore, depending on the problem, chronic renal disease (CRD) often allows time before renal replacement therapy (RRT) is needed. RRT currently is dialysis (peritoneal or hemodialysis) or renal transplant. In general, the patient’s own kidneys do the best job for them but there is always a balance between the problems of CRD and its management, versus the potentially improved renal function with RRT. RRT itself though has a diffe...
Source: PediatricEducation.org - September 13, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

FDA Clears Thermo Scientific EliA SmD(P)-S Test For Use In U.S.
New blood test is designed to reduce the number of false positive results and provide improved diagnostic guidance in Systemic Lupus Erythematosus PORTAGE, Mich., Aug. 26, 2021 -- (Healthcare Sales & Marketing Network) -- Thermo Scientific EliA SmDP-S ... Diagnostics, FDA Thermo Fisher Scientific, EliA SmDP-S, Systemic Lupus Erythematosus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2021 Category: Pharmaceuticals Source Type: news

Experts Debate Merits of Dual Therapy for Lupus Nephritis Experts Debate Merits of Dual Therapy for Lupus Nephritis
Brad Rovin, MD, and Richard Furie, MD, discussed the merits of dual therapy with voclosporin or belimumab in lupus nephritis but said response rates leave a lot of room for improvement.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 19, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

CAR T-Cell Therapy Drives Refractory SLE Into Remission CAR T-Cell Therapy Drives Refractory SLE Into Remission
B-cell depletion with chimeric antigen receptor T cells induced both serologic and clinical remissions in a patient with treatment-resistant lupus.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 13, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

COVID-19 Booster Shots Are Still Controversial —Even for the Immunocompromised People Who Likely Need Them the Most
Chris Neblett, 44, was among the first people in the U.S. to get vaccinated against COVID-19. His job with the U.S. State Department allowed him to get his initial dose of Pfizer-BioNTech’s vaccine in late December 2020. By January 2021, he was fully vaccinated. But that didn’t mean he was fully protected. Neblett, who received a kidney transplant in 2018 and still takes immune-system-suppressing drugs to prevent his body from rejecting the organ, found out through his participation in a Johns Hopkins study of vaccination among transplant patients that he didn’t produce any disease-fighting antibodies, ev...
Source: TIME: Health - August 11, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news

CAR T-Cell Immunotherapy Rids Woman of Tough-to-Treat Lupus
Title: CAR T-Cell Immunotherapy Rids Woman of Tough-to-Treat LupusCategory: Health NewsCreated: 8/5/2021 12:00:00 AMLast Editorial Review: 8/6/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 6, 2021 Category: Rheumatology Source Type: news

CAR T-Cell Immunotherapy Rids Woman of Tough-to-Treat Lupus
Researchers have used genetically tweaked immune system cells to send a woman's severe lupus into remission. (Source: WebMD Health)
Source: WebMD Health - August 5, 2021 Category: Consumer Health News Source Type: news

CAR T-Cell Immunotherapy Rids Woman of Tough-to-Treat Lupus
THURSDAY, Aug. 5, 2021 -- In a first, researchers have used genetically tweaked immune system cells to send a woman's severe lupus into remission. The treatment -- called CAR T-cell therapy -- is already approved in the United States for fighting... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 5, 2021 Category: General Medicine Source Type: news

Arthritis, lupus flares rare after COVID-19 vaccination, study finds
The COVID-19 vaccine rarely causes flares in people with rheumatoid arthritis and lupus, according to a study published Wednesday by the journal Arthritis and Rheumatology. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 4, 2021 Category: Consumer Health News Source Type: news

FDA Approves Anifrolumab (Saphnelo) as New Lupus Treatment FDA Approves Anifrolumab (Saphnelo) as New Lupus Treatment
Anifrolumab, a monoclonal antibody against type 1 interferon receptor, improved overall disease activity in patients with SLE on standard therapy, according to data from three trials.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 2, 2021 Category: Dermatology Tags: Rheumatology News Alert Source Type: news

FDA Approves Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus Erythematosus
2 August 2021 -- AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.1 The approval by the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 2, 2021 Category: Drugs & Pharmacology Source Type: news

COVID Vax Does Not Increase Risk of Flare in Patients With Lupus COVID Vax Does Not Increase Risk of Flare in Patients With Lupus
An international web-based survey found a very low rate of medically confirmed flare post COVID vaccination in nearly 700 participants.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 28, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Fifteen years in the making, biotech lands in Bay Area with fresh funding from Hyatt heirs and plan to change direction of inflammatory diseases
Giant drug maker Bristol-Myers Squibb and a string of investment vehicles led by heirs of the Hyatt Hotels fortune invested in a North Bay company tapping deep patient data to move faster to discover and develop drugs against lupus, Crohn's disease and other inflammatory diseases. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 27, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

SLE Neuropsych Event Etiology Helps Define Predictors, Outcomes SLE Neuropsych Event Etiology Helps Define Predictors, Outcomes
Male sex, active systemic lupus erythematosus, and corticosteroid use were among the factors positively associated with neuropsychiatric events in patients with SLE.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 10, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

NYUAD study maps nanobody structure, leading to new ways to potentially fight diseases
(New York University) For the first time in the UAE, researchers at NYU Abu Dhabi have used nuclear magnetic resonance techniques to determine the structure of a specific nanobody, Nb23, potentially leading to a better understanding of how this small protein derived from an antibody type, found only in camelids (i.e camels, llamas, and alpacas) and sharks, can fight diseases ranging from rheumatoid arthritis, lupus and psoriasis to lymphoma and breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: news

NIDCR's Summer 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR to Release Report on Oral Health in America As a 20-year follow-up to the seminal Oral Health in America: A Report of the Surgeon General, NIDCR will release Oral Health in America: Advances and Challenges in the fall of 2021. The report will illuminate new directions...
Source: NIDCR Science News - July 1, 2021 Category: Dentistry Source Type: news

Accelerating Lupus Drug Discovery & Development: Fireside Chat...
This webinar will feature a discussion of advancements and critical milestones to date in SLE research and drug discovery. It will explore key considerations for improving both research into SLE, as...(PRWeb June 28, 2021)Read the full story at https://www.prweb.com/releases/accelerating_lupus_drug_discovery_development_fireside_chat_with_experts_in_sle_research_upcoming_webinar_hosted_by_xtalks/prweb18034256.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 28, 2021 Category: Pharmaceuticals Source Type: news

Lupus Images Fall Short in Diversity Lupus Images Fall Short in Diversity
Medical resources in general have historically underrepresented patients of color.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 18, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Dacrocystitis in a Teenager?
Discussion Tears are produced in the lacrimal gland which resides in the upper outer quadrant of the eye. The tears flow across the eye medially and are collected in the superior and inferior puncta which drain into their respective canaliculi, and these drain into a common canaliculus. Tears then pass through the valve of Rosenmuler into the lacrimal sac where they are collected. Tears then pass through the nasolacrimal duct, through the distal valve of Hasner and into the nasal cavity. Vascular connections are extensive in this anatomic area and veins do not have valves. Therefore infections can spread easily through dir...
Source: PediatricEducation.org - June 14, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares
Results from a phase 2b trial are"clearly encouraging" and"support the hypothesis that BAFF [B-cell-activating factor] can drive flares after rituximab," said Michael Ehrenstein, MD.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 4, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Add-On Voclosporin Improves Outcome in Lupus Nephritis Add-On Voclosporin Improves Outcome in Lupus Nephritis
Voclosporin plus MMF and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

Experimental Treatment Offers New Hope Against Lupus
Title: Experimental Treatment Offers New Hope Against LupusCategory: Health NewsCreated: 5/27/2021 12:00:00 AMLast Editorial Review: 5/28/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 28, 2021 Category: Rheumatology Source Type: news

Rheumatoid arthritis and systemic lupus erythematosus during COVID-19 quarantine period
This study aimed to investigate self-reported symptoms of disease flares among patients with rheumatoid arthritis or systemic lupus erythematosus during the COVID-19 pandemic. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2021 Category: International Medicine & Public Health Source Type: news

Experimental Treatment Offers New Hope Against Lupus
A small, early "phase 1" trial finds an experimental antibody therapy may help ease skin symptoms from the autoimmune disease lupus. (Source: WebMD Health)
Source: WebMD Health - May 27, 2021 Category: Consumer Health News Source Type: news

Experimental Treatment Offers New Hope Against Lupus
THURSDAY, May 27, 2021 -- An experimental antibody therapy may help ease skin symptoms from the autoimmune disease lupus, a small preliminary trial suggests. Researchers found that a higher-dose version of the drug spurred a " clinically meaningful " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 27, 2021 Category: General Medicine Source Type: news

Biotech firm Asylia Therapeutics raises $14.5M, names founding CEO
Houston-based biotechnology firm Asylia Therapeutics Inc. raised $14.5 million to advance its clinical trials for cancer drugs. The Series A round was led by Houston-based Sporos Bioventures, Asylia announced May 25. The company will use proceeds to bring Asylia's assets to first-in-human clinical trials for oncology. Asylia could potentially generate proof-of-concept signals for its clinical assets in treating autoimmune diseases like lupus, the firm said. "While cancer research has come a significant… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 25, 2021 Category: Biotechnology Authors: Chris Mathews Source Type: news

Rogue antibodies wreak havoc in severe COVID-19 cases
The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in severe cases of COVID-19, Yale scientists report in the journal Nature. These autoantibodies target and react with a person's tissues or organs similar to ones that cause autoimmune diseases such as lupus or rheumatoid arthritis. (Source: World Pharma News)
Source: World Pharma News - May 19, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

How Is Lupus Nephritis Treated
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 12, 2021 Category: General Medicine Source Type: news